Richard Coulon

Title: The Innovations of Richard Coulon

Introduction

Richard Coulon is an accomplished inventor based in Cummings, GA (US). He has made significant contributions to the field of medical formulations, particularly in the treatment of dry eye syndrome. His innovative approach has led to the development of a unique patent that addresses a common yet often overlooked condition.

Latest Patents

Richard Coulon holds a patent for "Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application." This patent focuses on a topical application formulation that utilizes estrogen and its analogs to treat primary or secondary dry eye syndrome, also known as keratoconjunctivitis sicca (KCS). The preferred formulations include 17-β-estradiol and its derivatives, which are delivered in lipid, liposomes, polymers, or aqueous and non-aqueous vehicles. These formulations are designed for time-release or micro-dose applications, particularly beneficial for the ocular surface tissues. Additionally, they may be useful in treating conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients. Richard has 1 patent to his name.

Career Highlights

Richard Coulon is currently associated with Redwood Pharma AB, where he continues to innovate in the field of pharmaceutical formulations. His work has been instrumental in advancing treatment options for patients suffering from dry eye syndrome.

Collaborations

Richard has collaborated with notable professionals in his field, including Clive H Reading and Thomas L Rowe. Their combined expertise has contributed to the development of effective treatment solutions.

Conclusion

Richard Coulon's contributions to the field of medical formulations, particularly in the treatment of dry eye syndrome, highlight his innovative spirit and dedication to improving patient care. His patent represents a significant advancement in topical applications for this condition.